Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2023-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Vaccines made from DNA or a gene-modified virus may help the body build an effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Applying topical imiquimod to the cervix may be an effective treatment for cervical intraepithelial neoplasia. Giving vaccine therapy together with imiquimod may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy and to see how well it works when given with or without imiquimod in treating patients with grade 3 cervical intraepithelial neoplasia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

NCT03911076

ASC-US ASC-H LSIL

TERMINATED PHASE2

Study of Treatment for HPV16+ ASC-US or LSIL

NCT03913117

ASC-US LSIL

RECRUITING PHASE1

Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.

NCT03206138

Cervical Intraepithelial Neoplasia 3

UNKNOWN NA

Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL

NCT02689726

HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL

TERMINATED PHASE1

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

NCT05584332

Cervical Cancer Genital Wart CIN1 +9 more

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* To evaluate safety, tolerability, and feasibility of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and TA-HPV vaccine with or without imiquimod in patients with human papillomavirus (HPV)16-positive grade 3 cervical intraepithelial neoplasia (CIN3).

Secondary

* To evaluate the effect of this regimen on histology, based on the regression of cervical intraepithelial neoplasia.
* To evaluate the feasibility and safety of study immunotherapy in these patients.
* To evaluate the quantitative changes in cervical HPV viral load in these patients following study immunotherapy.
* To evaluate changes in lesion size.
* To evaluate the cellular and humoral immune response to vaccination.
* To evaluate local tissue immune response.
* To correlate measures of immune response with clinical response.
* To correlate measures of immune response with those observed in the preclinical model.
* To evaluate if the efficacy of the prime-boost vaccination can be improved with the cervical application of imiquimod.

OUTLINE: This is a dose escalation study of TA-HPV vaccine (groups 1-3 only). Patients are assigned to 1 of 5 treatment groups.

* Groups 1-3: Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine intramuscularly (IM) in weeks 0 and 4 and TA-HPV vaccine IM in week 8.
* Group 4: Patients receive topical imiquimod applied to the cervix once in weeks 0, 4, and 8.
* Group 5: Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and TA-HPV vaccine as in groups 1-3, and imiquimod as in group 4.

Patients experiencing no improvement of their lesions at week 15 undergo standard cone resection of the squamocolumnar junction. If there is either 1) regression of the size of the lesions by colposcopy and/or 2) no CIN3 lesions detected by colposcopy/biopsy and Pap smear and/or 3) significant decrease of HPV viral load, patients are followed until week 28. At that time, loop electrosurgical excision procedure (LEEP) resection is performed if there is a CIN3 lesion detected by colposcopy/biopsy or suspected by Pap smear. Patients undergoing LEEP are followed until week 32. Patients not undergoing LEEP are followed until week 41 to confirm CIN3 regression.

Blood and tissue samples are collected periodically to measure immune response via ELISA, determine viral load and identify co-infecting HPV types via reverse-line blotting, and analyze lymphocytes via flow cytometry.

PROJECTED ACCRUAL: A total of 36 patients (3 in groups 1 and 2, 12 in groups 3 and 5, and 6 in group 4) will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Cancer Precancerous Condition HPV Disease Human Papilomavirus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TA-HPV

Given intramuscularly

Intervention Type BIOLOGICAL

pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine

Given intramuscularly

Intervention Type BIOLOGICAL

imiquimod

Given topically

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Colposcopically and biopsy confirmed grade 3 cervical intraepithelial neoplasia

* Human papillomavirus (HPV) 16-positive disease by PCR
* Measurable disease after diagnostic biopsy
* No concurrent adenocarcinoma in situ of the cervix

PATIENT CHARACTERISTICS:

* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use an effective form of contraception during study treatment
* Immunocompetent
* No concurrent malignancy, except for nonmelanoma skin lesions
* No serious concurrent disorder, including any of the following:

* Active systemic infection
* Autoimmune disease
* Proven or suspected immunosuppressive disorder
* Major medical illnesses of the cardiovascular or respiratory system
* No evidence or history of cardiac disease, including any of the following:

* Congestive heart failure
* Symptomatic arrhythmia not controlled by medication
* Unstable angina
* History of acute myocardial infarction or cerebrovascular accident within the past 6 months
* No history of severe allergy including eczema or other exfoliative skin disorder
* No active eczema within the past 12 months
* No concurrent skin conditions, including any of the following:

* Burns
* Traumatic or pruritic skin conditions
* Open wounds
* Unhealed surgical scars
* Patients and their close social, sexual, or domestic contacts may not have any of the following active skin diseases:

* Psoriasis
* Lichen planus
* Sever acneiform rash
* Impetigo
* Varicella zoster
* Sepsis
* No close social contact with children under 5 years old
* No close social or domestic contact with a pregnant woman
* No HIV seropositivity
* No allergy to eggs

PRIOR CONCURRENT THERAPY:

* No previous vaccination with vaccinia
* No immunosuppressive medication (i.e., steroid therapy or other immunosuppressive/immunomodulating drugs \[e.g., cyclosporine\]) within the past 2 months
* No investigational agent(s) within the past 6 months
* No concurrent participation in another experimental protocol

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No